Natera says lung cancer MRD study links Signatera results to 3-year recurrence-free survival in 1,129 patients
NTRA•Clinical data from lung cancer MRD study
Natera disclosed clinical data already presented at the IASLC 2026 World Conference on Lung Cancer in Seoul.
The lung cancer study found Signatera MRD status following surgery helped identify patients more likely to relapse or die.
Results supported use in both early post-surgical assessment and ongoing monitoring, pointing to a potential role in guiding adjuvant treatment decisions.
The dataset covered 1,129 patients with resected stage 1-3 non-small cell lung cancer, spanning 2016 to 2025.
